Upstream Bio outlines Phase 3 plans for verekitug in asthma and CRSwNP
Upstream Bio says it will study 400 mg verekitug every 12 weeks versus placebo in severe asthma and CRSwNP, using one pivotal Phase 3 trial per indication after FDA discussions.
Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication —— The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both…